BioScrip Earnings: Here’s Why Investors are Buying Shares Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

BioScrip, Inc. (NASDAQ:BIOS) delivered a profit and met Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are up 2.28%.

BioScrip, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $0.04 in the quarter versus EPS of $-0.07 in the year-earlier quarter.

Revenue: Rose 22.34% to $190.73 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: BioScrip, Inc. reported adjusted EPS income of $0.04 per share. By that measure, the company missed the mean analyst estimate of $0.04. It missed the average revenue estimate of $206.47 million.

Quoting Management: “The infusion business again posted robust organic growth and reflects continued progress in the execution of our infusion-focused strategy. Our goals of expanding infusion margins and generating operating leverage are consistent with our expectations and are beginning to yield results. We remain focused on the key growth drivers of our business and our strategic plan. In the quarter, however, our results were impacted by weaker-than-expected contributions from our PBM segment,” said Rick Smith, President and Chief Executive Officer of BioScrip.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business